Global expansion Akesis is actively advancing its radiation therapy platforms internationally and has existing partnerships and collaborations with providers and organizations, presenting opportunities to expand distribution, integration services, and regional support agreements in oncology markets.

Clinical collaborations Recent and ongoing partnerships with University Hospitals Seidman Cancer Center, MagnetTx, Zahrawi Group, and others indicate a proven path to access reputable cancer centers for pilots, case studies, and potential multi-site implementations to accelerate adoption.

Adaptive therapy edge The Gemini360RT supports online and offline adaptive therapy while Galaxy RTi enables precise stereotactic radiosurgery with real-time imaging, offering a compelling value proposition for clinics seeking to upgrade to adaptive and high-precision treatment capabilities.

Regulatory readiness FDA 510(k) clearance for Gemini360RT and FDA-clearance for Galaxy RTi suggest a relatively favorable regulatory posture, which can be leveraged in sales messaging to reduce perceived risk for hospitals and oncology centers considering new equipment.

Mid-market focus With a revenue profile in the 1–10 million range and a lean team, Akesis appears positioned to target mid-market cancer centers and regional networks seeking advanced radiation systems with strong service and regulatory backing, offering compelling ROI and serviceability.